Risk factors for serious infections in ANCA-associated vasculitis.

Balazs OdlerRegina RiedlPhilipp GaucklerJae Il ShinJohannes LeiererPeter A MerkelWilliam St ClairFernando FervenzaDuvuru GeethaPaul MonachDavid R W JayneRona M SmithAlexander RosenkranzUlrich SpecksJohn H Stone Andreas Kronbichlernull null

Published in: Annals of the rheumatic diseases (2023)

The use of low-dose TMP/SMX is associated with reduced risk of severe infections in patients with AAV treated with either RTX or CYC/AZA. Reduced B cell subpopulations at start of treatment might be a useful correlate of reduced immunocompetence.

Keyphrases

low dose
high dose

early onset

gene therapy

replacement therapy